Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yudi Mulyana Hidayat, Munizar, Ali Budi Harsono, Gatot Nyarumenteng Adhipurnawan Winarno, Hasanuddin & Siti Salima. (2020) Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer. International Journal of General Medicine 13, pages 1201-1206.
Read now
Read now
Sunu Lazar Cyriac, Katherine Karakasis & Amit M. Oza. (2018) Rucaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs 6:2, pages 151-161.
Read now
Read now
Luisa Bonilla, Amit Oza & Stephanie Lheureux. (2018) Emerging growth factor receptor antagonists for ovarian cancer treatment. Expert Opinion on Emerging Drugs 23:1, pages 1-16.
Read now
Read now
Heather J. Bax, Debra H. Josephs, Giulia Pellizzari, James F. Spicer, Ana Montes & Sophia N. Karagiannis. (2016) Therapeutic targets and new directions for antibodies developed for ovarian cancer. mAbs 8:8, pages 1437-1455.
Read now
Read now
Zhijie Wang & Siqing Fu. (2016) An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opinion on Investigational Drugs 25:1, pages 15-30.
Read now
Read now
Ji Xue, Guang Yang, Hong Ding, Pu Wang & Changhong Wang. (2015) Role of NSC319726 in ovarian cancer based on the bioinformatics analyses. OncoTargets and Therapy 8, pages 3757-3765.
Read now
Read now
Articles from other publishers (71)
Aideen McCabe, Oza Zaheed, Simon Samuel McDade & Kellie Dean. (2023) Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Najeebul Tarfeen, Khair Ul Nisa, Shafat Ali, Ali Mohd Yatoo, Aabid Manzoor Shah, Anjum Sabba, Rouf Maqbool & Mir Bilal Ahmad. 2023. Proteomics. Proteomics
319
332
.
Tianyue Xu, Zhihui Liu, Liwen Huang, Jing Jing & Xiaowei Liu. (2022) Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Urushi Rehman, Neha Parveen, Afsana Sheikh, Mohammed A.S. Abourehab, Amirhossein Sahebkar & Prashant Kesharwani. (2022) Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer. Colloids and Surfaces B: Biointerfaces 218, pages 112766.
Crossref
Crossref
Aashiq Hussain Bhat, Khalid Bashir Dar, Andleeb Khan, Saeed Alshahrani, Sultan M. Alshehri, Mohammed M. Ghoneim, Prawez Alam & Faiyaz Shakeel. (2022) Tricyclodecan-9-yl-Xanthogenate (D609): Mechanism of Action and Pharmacological Applications. International Journal of Molecular Sciences 23:6, pages 3305.
Crossref
Crossref
Marisol Salgado-Albarrán, Julian Späth, Rodrigo González-Barrios, Jan Baumbach & Ernesto Soto-Reyes. (2022) CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy. npj Systems Biology and Applications 8:1.
Crossref
Crossref
Abeer M. El-Saudi, Miram A. Altouhamy, Saad Shaaban, Farid A. Badria, Magdy M. Youssef & Fardous F. El-Senduny. (2022) Down regulation of fatty acid synthase via inhibition of PI3K/AKT/mTOR in ovarian cancer cell line by novel organoselenium pseudopeptide. Current Research in Pharmacology and Drug Discovery 3, pages 100134.
Crossref
Crossref
Namrata Dwivedi & Priyanka Saha. 2022. Advances in Nanotechnology-Based Drug Delivery Systems. Advances in Nanotechnology-Based Drug Delivery Systems
321
342
.
Matthew J. Regner, Kamila Wisniewska, Susana Garcia-Recio, Aatish Thennavan, Raul Mendez-Giraldez, Venkat S. Malladi, Gabrielle Hawkins, Joel S. Parker, Charles M. Perou, Victoria L. Bae-Jump & Hector L. Franco. (2021) A multi-omic single-cell landscape of human gynecologic malignancies. Molecular Cell 81:23, pages 4924-4941.e10.
Crossref
Crossref
Zhe Wang, Fenghua Meng & Zhiyuan Zhong. (2021) Emerging targeted drug delivery strategies toward ovarian cancer. Advanced Drug Delivery Reviews 178, pages 113969.
Crossref
Crossref
Anjali Geethadevi, Ajay Nair, Deepak Parashar, Zhiqiang Ku, Wei Xiong, Hui Deng, Yongsheng Li, Jasmine George, Donna M. McAllister, Yunguang Sun, Ishaque P. Kadamberi, Prachi Gupta, Michael B. Dwinell, William H. Bradley, Janet S. Rader, Hallgeir Rui, Robert F. Schwabe, Ningyan Zhang, Sunila Pradeep, Zhiqiang An & Pradeep Chaluvally-Raghavan. (2021) Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. Cancer Research 81:20, pages 5336-5352.
Crossref
Crossref
Krisztina S. Nagy, Krisztina Toth, Eva Pallinger, Angela Takacs, Laszlo Kohidai, Angela Jedlovszky-Hajdu, Domokos Mathe, Noemi Kovacs, Daniel S. Veres, Krisztian Szigeti, Kristof Molnar, Eniko Krisch & Judit E. Puskas. (2021) Folate-Targeted Monodisperse PEG-Based Conjugates Made by Chemo-Enzymatic Methods for Cancer Diagnosis and Treatment. International Journal of Molecular Sciences 22:19, pages 10347.
Crossref
Crossref
Eric N. Horst, Michael E. Bregenzer, Pooja Mehta, Catherine S. Snyder, Taylor Repetto, Yang Yang-Hartwich & Geeta Mehta. (2021) Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. Acta Biomaterialia 132, pages 401-420.
Crossref
Crossref
Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel Berg, James S. Garner & Don S. Dizon. (2021) Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers 13:13, pages 3196.
Crossref
Crossref
Amreen Salwa, Alessandra Ferraresi, Menaka Chinthakindi, Letizia Vallino, Chiara Vidoni, Danny N. Dhanasekaran & Ciro Isidoro. (2021) BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis. Biomedicines 9:2, pages 207.
Crossref
Crossref
Yan Liu, Ling Li, Xiangyang Wang, Ping Wang & Zhongxian Wang. (2020) LncRNA TONSL-AS1 regulates miR-490-3p/CDK1 to affect ovarian epithelial carcinoma cell proliferation. Journal of Ovarian Research 13:1.
Crossref
Crossref
Ding Zhu, Xueshuang Huang, Fang Liang & Lijing Zhao. (2020) RETRACTED ARTICLE: LncRNA miR503HG interacts with miR-31-5p through multiple ways to regulate cancer cell invasion and migration in ovarian cancer. Journal of Ovarian Research 13:1.
Crossref
Crossref
Adam C. Palmer, Deborah Plana, Hui Gao, Joshua M. Korn, Guizhi Yang, John Green, Xiamei Zhang, Roberto Velazquez, Margaret E. McLaughlin, David A. Ruddy, Colleen Kowal, Julie Muszynski, Caroline Bullock, Stacy Rivera, Daniel P. Rakiec, GiNell Elliott, Paul Fordjour, Ronald Meyer, Alice Loo, Esther Kurth, Jeffrey A. Engelman, Hans Bitter, William R. Sellers, Juliet A. Williams & Peter K. Sorger. (2020) A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts. Cancer Research 80:19, pages 4278-4287.
Crossref
Crossref
Xiaoqing Wang, Xiao Xu, Guoqiang Jiang, Cuili Zhang, Likun Liu, Jian Kang, Jing Wang, Lawrence Owusu, Liye Zhou, Lin Zhang & Weiling Li. (2020) Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. Journal of Cellular and Molecular Medicine 24:19, pages 11177-11187.
Crossref
Crossref
Xiang-Qi Zhang, Ya-Wei Ding, Jun-Jun Chen, Xiao Xiao, Wei Zhang, Li Zhou, Qian-Wen Kong, Mei-Zhi Shi, Jiao Yang, Bo Jiang, Cheng Guo & Yong-Long Han. (2020) Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules. Journal of Ethnopharmacology 261, pages 113067.
Crossref
Crossref
Alba Mota, Sara S Oltra & Gema Moreno-Bueno. (2020) Insight updating of the molecular hallmarks in ovarian carcinoma. European Journal of Cancer Supplements 15, pages 16-26.
Crossref
Crossref
Seema Khadirnaikar, Pranjal Kumar & Sudhanshu Kumar Shukla. (2019) Development and validation of an immune prognostic signature for ovarian carcinoma. CANCER REPORTS 3:4.
Crossref
Crossref
Ricardo Roque, Filipa Costa Sousa & Margarida Figueiredo-Dias. (2020) Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination. Oncology Reviews 14:2.
Crossref
Crossref
Jonathan M. Pantshwa, Pierre P. D. Kondiah, Yahya E. Choonara, Thashree Marimuthu & Viness Pillay. (2020) Nanodrug Delivery Systems for the Treatment of Ovarian Cancer. Cancers 12:1, pages 213.
Crossref
Crossref
Xiaoran Long, Keqi Song, Hao Hu, Qi Tian, Wenjing Wang, Qian Dong, Xia Yin & Wen Di. (2019) Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Yuan Wang, Xia Lei, Chengying Gao, Yanxia Xue, Xiaolin Li, Haiying Wang & Yan Feng. (2019) MiR-506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6. Journal of Biosciences 44:6.
Crossref
Crossref
Clara Bodelon, J. Keith Killian, Joshua N. Sampson, William F. Anderson, Rayna Matsuno, Louise A. Brinton, Jolanta Lissowska, Michael S. Anglesio, David D.L. Bowtell, Jennifer A. Doherty, Susan J. Ramus, Aline Talhouk, Mark E. Sherman & Nicolas Wentzensen. (2019) Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. Clinical Cancer Research 25:19, pages 5937-5946.
Crossref
Crossref
Bruna Corradetti, Simone Pisano, Robert Steven Conlan & Mauro Ferrari. (2019) Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes. Journal of Pharmacology and Experimental Therapeutics 370:3, pages 636-646.
Crossref
Crossref
Hongmei Li, Meihua Lv, Baohua Qiao & Xia Li. (2019) Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer. Archives of Gynecology and Obstetrics 299:6, pages 1737-1746.
Crossref
Crossref
Bo‑Im Kim, Ju‑Ha Kim, Deok Yong Sim, Minho Nam, Ji Hoon Jung, Bumsang Shim, Jaeyeol Lee & Sung‑Hoon Kim. (2019) Inhibition of JAK2/STAT3 and activation of caspase‑9/3 are involved in KYS05090S‑induced apoptosis in ovarian cancer cells. International Journal of Oncology.
Crossref
Crossref
Michelle S LinAlberto G AyalaJae Y Ro. (2019) Ovarian-type Tumors (Mullerian Tumors) of the Testis: Clinicopathologic Findings with Recent Advances. annals of urologic oncology, pages 1-9.
Crossref
Crossref
Manuel Nolasco‑Quiroga, Marisol Rosas‑D�az, Jos� Moreno, Ricardo God�nez‑Aguilar, Mar�a L�pez‑Ibarra, Patricia Pi�a‑S�nchez, Isabel Alvarado‑Cabrero, Gerardo V�zquez‑G�mez, Leticia Rocha‑Zavaleta, Diego Arenas‑Aranda & Fabio Salamanca‑G�mez. (2019) Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer. Oncology Letters.
Crossref
Crossref
Hassan Yousefi, Majid Momeny, Seyed H. Ghaffari, Nazanin Parsanejad, Arash Poursheikhani, Sepehr Javadikooshesh, Ghazaleh Zarrinrad, Fatemeh Esmaeili, Zivar Alishahi, Zahra Sabourinejad, Ghazaleh Sankanian, Sahar Shamsaiegahkani, Davood Bashash, Narjes Shahsavani, Javad Tavakkoly-Bazzaz, Kamran Alimoghaddam & Ardeshir Ghavamzadeh. (2018) IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. Tumori Journal 105:1, pages 84-91.
Crossref
Crossref
Margaux J. Kanis, Wenan Qiang, Mario Pineda, Kruti P. Maniar & J. Julie Kim. (2018) A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer. Gynecologic Oncology Research and Practice 5:1.
Crossref
Crossref
E. A. Braga, V. I. Loginov, E. A. Filippova, A. M. Burdennyi, I. V. Pronina, T. P. Kazubskaya, D. S. Khodyrev, D. O. Utkin, D. N. Kushlinskii, L. V. Adamyan & N. E. Kuslinskii. (2018) Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma. Bulletin of Experimental Biology and Medicine 166:2, pages 253-256.
Crossref
Crossref
А.М. Бурдённый, Д.О. Уткин, Е.А. Филиппова, В.И. Логинов, И.В. Пронина, М.В. Фридман, Т.П. Казубская, Н.Е. Кушлинский & Э.А. Брага. (2018) Hypermethylation of a group of microRNA genes in primary tumors and peritoneal metastases of ovarian cancer. ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»:4(), pages 58-66.
Crossref
Crossref
Maria Barbolina. (2018) Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma. Cancers 10:11, pages 444.
Crossref
Crossref
Jeff Hirst, Jennifer Crow & Andrew Godwin. 2018. Ovarian Cancer - From Pathogenesis to Treatment. Ovarian Cancer - From Pathogenesis to Treatment.
Jinhui Liu, Yi Jiang, Yicong Wan, Shulin Zhou, Sunita Thapa & Wenjun Cheng. (2018) MicroRNA‑665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10. Molecular Medicine Reports.
Crossref
Crossref
Vitaly I. Loginov, Irina V. Pronina, Alexey M. Burdennyy, Elena A. Filippova, Tatiana P. Kazubskaya, Dmitry N. Kushlinsky, Dmitry O. Utkin, Dmitry S. Khodyrev, Nikolay E. Kushlinskii, Alexey A. Dmitriev & Eleonora A. Braga. (2018) Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis. Gene 662, pages 28-36.
Crossref
Crossref
Arkene Levy & Patricia C. Rose. 2018. Cancer Management and Therapy. Cancer Management and Therapy.
Ji Hee Ha, Rangasudhagar Radhakrishnan, Muralidharan Jayaraman, Mingda Yan, Jeremy D. Ward, Kar-Ming Fung, Katherine Moxley, Anil K. Sood, Ciro Isidoro, Priyabrata Mukherjee, Yong Sang Song & Danny N. Dhanasekaran. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research 78:8, pages 1923-1934.
Crossref
Crossref
Soozana Puvanenthiran, Sharadah Essapen, Ben Haagsma, Izhar Bagwan, Margaret Green, Said Abdullah Khelwatty, Alan Seddon & Helmout Modjtahedi. (2018) Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer. Oncotarget 9:28, pages 19662-19674.
Crossref
Crossref
Tara Byrne, Laura Nelson, James P. Beirne, Daniel Sharpe, Jennifer E. Quinn, W. Glenn McCluggage, Tracy Robson & Fiona Furlong. (2018) BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma. International Journal of Gynecologic Cancer 28:3, pages 472-478.
Crossref
Crossref
Johnny R. Ramroop, Mark N. Stein & Justin M. Drake. (2018) Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer. Frontiers in Oncology 8.
Crossref
Crossref
Huang-Chiao Huang, Joyce Liu, Yan Baglo, Imran Rizvi, Sriram Anbil, Michael Pigula & Tayyaba Hasan. (2018) Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis. Molecular Cancer Therapeutics 17:2, pages 508-520.
Crossref
Crossref
Lynn Roy, Alexander Bobbs, Rachel Sattler, Jeffrey L Kurkewich, Paige B Dausinas, Prakash Nallathamby & Karen D Cowden Dahl. (2018) CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche. Cancer Growth and Metastasis 11, pages 117906441876788.
Crossref
Crossref
Signe Ladegaard Harder & Jørn Herrstedt. 2018. The MASCC Textbook of Cancer Supportive Care and Survivorship. The MASCC Textbook of Cancer Supportive Care and Survivorship
505
526
.
Robert Cornelison, Danielle Llaneza & Charles Landen. (2017) Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. International Journal of Molecular Sciences 18:10, pages 2171.
Crossref
Crossref
Joydeep Das, Yun-Jung Choi, Jae Woong Han, Abu Musa Md Talimur Reza & Jin-Hoi Kim. (2017) Nanoceria-mediated delivery of doxorubicin enhances the anti-tumour efficiency in ovarian cancer cells via apoptosis. Scientific Reports 7:1.
Crossref
Crossref
Yi-Fei Chen, Shu-Ying Wang, You-Hui Yang, Jiang Zheng, Ting Liu & Li Wang. (2017) Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer. International Journal of Molecular Medicine 39:6, pages 1564-1570.
Crossref
Crossref
Long Huang, Yun Zhou, Xin-Ping Cao, Jia-Xin Lin, Lan Zhang, Shu-Ting Huang & Min Zheng. (2017) KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis. Tumor Biology 39:6, pages 101042831770628.
Crossref
Crossref
Seyedeh Atekeh Torabizadeh, Seyed Mohammad Abedi, Zohreh Noaparast & Seyed Jalal Hosseinimehr. (2017) Comparative assessment of a 99m Tc labeled H1299.2-HYNIC peptide bearing two different co-ligands for tumor-targeted imaging. Bioorganic & Medicinal Chemistry 25:9, pages 2583-2592.
Crossref
Crossref
Matthew Choo, Heng Liang Tan, Vanessa Ding, Roberto Castangia, Omar Belgacem, Brian Liau, Lauren Hartley-Tassell, Stuart M. Haslam, Anne Dell & Andre Choo. (2017) Characterization of H type 1 and type 1 N-acetyllactosamine glycan epitopes on ovarian cancer specifically recognized by the anti-glycan monoclonal antibody mAb-A4. Journal of Biological Chemistry 292:15, pages 6163-6176.
Crossref
Crossref
Emiliano Cocco, Yang Deng, Erik M. Shapiro, Ileana Bortolomai, Salvatore Lopez, Ken Lin, Stefania Bellone, Jiajia Cui, Gulden Menderes, Jonathan D. Black, Carlton L. Schwab, Elena Bonazzoli, Fan Yang, Federica Predolini, Luca Zammataro, Gary Altwerger, Christopher de Haydu, Mitchell Clark, Julio Alvarenga, Elena Ratner, Masoud Azodi, Dan-Arin Silasi, Peter E. Schwartz, Babak Litkouhi, W. Mark Saltzman & Alessandro D. Santin. (2017)
Dual-Targeting Nanoparticles for
In Vivo
Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
. Molecular Cancer Therapeutics 16:2, pages 323-333.
Crossref
Crossref
Shunfei Yan, Daniel Frank, Jinbae Son, Katherine Hannan, Ross Hannan, Keefe Chan, Richard Pearson & Elaine Sanij. (2017) The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences 18:1, pages 210.
Crossref
Crossref
Miriana Hijaz, Soumen Das, Ismail Mert, Ankur Gupta, Zaid Al-Wahab, Calvin Tebbe, Sajad Dar, Jasdeep Chhina, Shailendra Giri, Adnan Munkarah, Sudipta Seal & Ramandeep Rattan. (2016) Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer. BMC Cancer 16:1.
Crossref
Crossref
Soroush Aalipour, Samaneh Zoghi, Nastaran Khalili, Armin Hirbod-Mobarakeh, Leisha A Emens & Nima Rezaei. (2016) Specific immunotherapy in ovarian cancer: a systematic review. Immunotherapy 8:10, pages 1193-1204.
Crossref
Crossref
Lorenza Mittempergher. (2016) Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies. Current Oncology Reports 18:7.
Crossref
Crossref
Hui Jun Lim & William Ledger. (2016) Targeted Therapy in Ovarian Cancer. Women's Health 12:3, pages 363-378.
Crossref
Crossref
Barbara Bukowska, Aneta Rogalska & Agnieszka Marczak. (2016) New potential chemotherapy for ovarian cancer — Combined therapy with WP 631 and epothilone B. Life Sciences 151, pages 86-92.
Crossref
Crossref
Laura Lehtinen, Pia Vesterkvist, Pia Roering, Taina Korpela, Liisa Hattara, Katja Kaipio, John-Patrick Mpindi, Johanna Hynninen, Annika Auranen, Ben Davidson, Caj Haglund, Kristiina Iljin, Seija Grenman, Harri Siitari & Olli Carpen. (2016) REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker. PLOS ONE 11:3, pages e0151590.
Crossref
Crossref
Alain B. Tchagang, Francois Fauteux & Youlian Pan. (2016) Integration of 3D gene expression patterns and gene regulatory networks for clinical applications in epithelial ovarian cancer. Integration of 3D gene expression patterns and gene regulatory networks for clinical applications in epithelial ovarian cancer.
ZHUO DENG, JIANCHENG ZHOU, XI HAN & XU LI. (2016) TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer. Oncology Reports 35:1, pages 359-365.
Crossref
Crossref
Irina V. Pronina, Vitaly I. Loginov, Alexey M. Burdennyy, Marina V. Fridman, Tatiana P. Kazubskaya, Alexey A. Dmitriev & Eleonora A. Braga. (2016) Expression and DNA methylation alterations of seven cancer-associated 3p genes and their predicted regulator miRNAs (miR-129-2, miR-9-1) in breast and ovarian cancers. Gene 576:1, pages 483-491.
Crossref
Crossref
Moon Sik Nam, Deok-Beom Jung, Kyeong-Hwa Seo, Bo-Im Kim, Ju-Ha Kim, Jung Hyo Kim, Bonglee Kim, Nam-In Baek & Sung-Hoon Kim. (2016) Apoptotic Effect of Sanggenol L via Caspase Activation and Inhibition of NF-κB Signaling in Ovarian Cancer Cells. Phytotherapy Research 30:1, pages 90-96.
Crossref
Crossref
Fatemeh GhaemimaneshAli Ahmad BayatSepideh BabaeiGholamreza AhmadianAmir-Hassan ZarnaniMehrdad BehmaneshMahmood Jeddi-TehraniHodjattallah Rabbani. (2015) Production and Characterization of a Novel Monoclonal Antibody Against Human Sortilin. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 34:6, pages 390-395.
Crossref
Crossref
Simran Preet, Sanjay Bharati, Anshul Panjeta, Rupinder Tewari & Praveen Rishi. (2015) Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis—a possible adjunct therapy. Tumor Biology 36:11, pages 8301-8308.
Crossref
Crossref
M. Zuberi, R. Mir, J. Das, I. Ahmad, J. Javid, P. Yadav, M. Masroor, S. Ahmad, P. C. Ray & A. Saxena. (2015) Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clinical and Translational Oncology 17:10, pages 779-787.
Crossref
Crossref
Bharat Devapatla, Ankur Sharma & Sukyung Woo. (2015) CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PLOS ONE 10:9, pages e0139237.
Crossref
Crossref
Daniela Rusu, Thomas Carlier, Mathilde Colombié, Dorothée Goulon, Vincent Fleury, Nicolas Rousseau, Dominique Berton-Rigaud, Isabelle Jaffre, Françoise Kraeber-Bodéré, Loic Campion & Caroline Rousseau. (2015) Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. Frontiers in Medicine 2.
Crossref
Crossref